Bernstein Liebhard is a leader in litigating cases involving dangerous drugs, defective medical devices and consumer products. Since its founding, the firm has successfully represented thousands of plaintiffs against some of the largest pharmaceutical, medical device and consumer products manufacturers in the world, winning more than $3.5 billion for our clients. In 2013, for example, the firm served on a trial team that recovered over $11 million for the plaintiff in the nation’s first trial involving an Ethicon pelvic mesh lawsuit. Our goal is to focus on your legal needs so that you and your family can focus on what is immediately important to you, which in most cases is medical treatment, recovery, caring for your family and continuing on with your life.
Bernstein Liebhard LLP’s impressive work in the area of mass tort litigation has earned widespread acclaim and been featured in various media outlets, including Bloomberg News and the New Jersey Law Journal.
The firm’s tireless advocacy on behalf of our clients has also been acknowledged by our peers in the legal community, with Senior Partner Sandy A. Liebhard repeatedly recognized as a “local litigation star” by Benchmark Plaintiff: The Definitive Guide to America’s Leading Plaintiff Firms & Attorneys (2012-2015 editions). In 2014, Mr. Liebhard was also recommended for his work in securities litigation by The Legal 500.
In 2017, partner Daniel C. Burke was recognized as a leader in the areas of class actions and mass torts by Super Lawyers magazine for the fifth consecutive year. Mr. Burke has also been appointed to leading roles in some of the nation’s most important mass tort litigations, including the Plaintiffs’ Steering Committee in In re: Biomet M2a Magnum Hip Implant Products Liability Litigation (MDL 2391); Liaison Counsel in the New York Coordinated Plavix-Related Proceedings (Index No. 560001/12); Plaintiffs’ Steering Committee in In re: Zimmer Nexgen Knee Implant Products Liability Litigation (MDL 2272); Discovery and Law & Briefing Sub-Committees for In re: Denture Cream Products Liability Litigation(MDL. 2051); and the Science and Discovery Sub-Committees for In re: Yasmin & Yaz (Drospirenone) Marketing, Sales Practices & Products Liability Litigation (MDL 2100).
The firm is currently pursuing cases involving a range of drugs, medical devices and consumer products, including:
- Nexium, Priolosec, Prevacid
- Hernia Mesh
- Cell Phone Radiation
- Diabetes Drugs and Pancreatic Cancer
- Prescription Testosterone Treatments
For updates on these and other cases currently being pursued by Bernstein Liebhard, please visit our consumer information website, RXInjuryHelp.com.